WETS
CRSP icon

Wealth Enhancement Trust Services’s CRISPR Therapeutics CRSP Stock Holding History

Wealth Enhancement Trust Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79M Sell
32,892
-5,961
-15% -$314K 0.2% 104
2026
Q1 		$1.85M Buy
38,853
+100
+0.3% +$5.27K 0.22% 92
2025
Q4 		$2.03M Buy
+38,753
New +$2.32M 0.26% 78

Other funds holding CRSP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wealth Enhancement Trust Services's CRSP Position: Q2 2026 in Review

Wealth Enhancement Trust Services reduced its CRISPR Therapeutics (CRSP) stake by 15% in Q2 2026, selling an estimated $314K and leaving 32,892 shares worth $1.79M. The position accounts for 0.2% of the portfolio, ranked #104.

Wealth Enhancement Trust Services first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.03M in Q4 2025. 349 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Wealth Enhancement Trust Services held 32,892 shares of CRISPR Therapeutics worth $1.79M as of Q2 2026.
  • Wealth Enhancement Trust Services sold 5,961 CRISPR Therapeutics shares in Q2 2026, an estimated $314K.
  • CRISPR Therapeutics made up 0.2% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #104 holding.
  • Wealth Enhancement Trust Services first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Wealth Enhancement Trust Services's CRISPR Therapeutics position peaked at $2.03M in Q4 2025.
  • 349 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.